(Q38219369)

31 August 2017

title

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy (English)

1 reference

31 August 2017

1 reference

Jing Lu

1

1 reference

31 August 2017

Linda Lee-Gabel

2

1 reference

31 August 2017

Michelle C Nadeau

3

1 reference

31 August 2017

Thomas M Ferencz

4

1 reference

31 August 2017

Scott A Soefje

5

1 reference

31 August 2017

publication date

9 June 2014

1 reference

Journal of Oncology Pharmacy Practice

31 August 2017

published in

1 reference

31 August 2017

volume

21

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

451-467

1 reference

Cancer immunotherapy comes of age

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Newer developments in the immunotherapy of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

The calm after the cytokine storm: lessons from the TGN1412 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

Update on immune checkpoint inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155214538087

21 January 2018

Identifiers

DOI

10.1177/1078155214538087

1 reference

31 August 2017

1 reference